References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailImpact of components of the metabolic syndrome on progression of knee osteoarthritis in the Sekoia study
Parsons, C; Edwards, MH; Eymard, F et al

in Osteoporosis International (2014), 25(2), 230

Detailed reference viewed: 28 (4 ULg)
Full Text
Peer Reviewed
See detailPreferences of patients for osteoporosis drug treatment: a cross-european discrete choice experiment
Hiligsmann, Mickaël ULg; Dellaert, BG; Dirksen, CD et al

in Osteoporosis International (2014), 25(2), 227-228

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailImpact of bone marrow lesion on the progression of knee osteoarthritis in the Sekoia study
Parsons, C; Edwards, MH; Bruyère, Olivier ULg et al

in Osteoporosis International (2014), 25(2), 142

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailPrognostic factors of death among nursing homes residents followed prospectively for a period of 2 years
Buckinx, Fanny ULg; Slomian, Justine ULg; Maquet, Didier ULg et al

in Osteoporosis International (2014), 25(2), 121-122

Detailed reference viewed: 24 (5 ULg)
Full Text
Peer Reviewed
See detailEvolution over two years of functional and motor abilities among nursing home residents
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Osteoporosis International (2014), 25(2), 121

Detailed reference viewed: 24 (7 ULg)
Full Text
Peer Reviewed
See detailPrevalence of sarcopenia according to different diagnostic tools
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Slomian, Justine ULg et al

in Osteoporosis International (2014), 25(2), 115

Detailed reference viewed: 29 (3 ULg)
Full Text
Peer Reviewed
See detailChallenges for the development of bone forming agents in Europe: introduction
Kanis, JA; Rizzoli, R; Cooper, C et al

in Osteoporosis International (2014), 25(2), 66-67

Detailed reference viewed: 20 (4 ULg)
Full Text
Peer Reviewed
See detailFurther reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension
Ferrari, S; Adachi, JD; Lippuner, K et al

in Osteoporosis International (2014), 25(2), 56

Detailed reference viewed: 61 (3 ULg)
Full Text
Peer Reviewed
See detailQuality of life benefits of knee arthroplasty for osteoarthritis
NEUPREZ, Audrey ULg; François, Garance ULg; KURTH, William ULg et al

in Osteoporosis International (2014), 25(2), 40

Detailed reference viewed: 60 (9 ULg)
Full Text
Peer Reviewed
See detailRisk factors for falls among elderly nursing home residents: a 2-year prospective study
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Osteoporosis International (2014), 25(2), 36-37

Detailed reference viewed: 73 (7 ULg)
Full Text
Peer Reviewed
See detailEvolution over two years of functional and motor abilities among nursing home residents
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Journal of Frailty & Aging (2014), 3(1), 45

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailPrevalence of sarcopenia according to different diagnostic tools
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Slomian, Justine ULg et al

in Journal of Frailty & Aging (2014), 3(1), 43

Detailed reference viewed: 64 (14 ULg)
Full Text
Peer Reviewed
See detailVitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux, Christian; Binkley, Neil; Boonen, Steven et al

in Calcified tissue international (2014), 94(2), 153-7

Vitamin D supplementation is recommended for women with osteoporosis. In the FOCUS-D trial comparing the combination tablet alendronate plus vitamin D3 5,600 IU (ALN/D) with standard care (SC) prescribed ... [more ▼]

Vitamin D supplementation is recommended for women with osteoporosis. In the FOCUS-D trial comparing the combination tablet alendronate plus vitamin D3 5,600 IU (ALN/D) with standard care (SC) prescribed by patients' personal physicians, ALN/D was more effective in improving serum 25(OH)D and bone turnover markers by 6 months and increasing spine and hip bone mineral density (BMD) after 1 year than SC. This post hoc analysis examined the relationship between BMD gain and 25(OH)D in women in SC receiving alendronate (SC/ALN, n = 134, 52% of the SC group) and in the ALN/D group (n = 257). At baseline, participants were of mean age 73 years and 72% were Caucasian, with a mean 25(OH)D of 14.9 ng/mL. In the SC/ALN group, most received vitamin D, although intake of vitamin D varied extensively (51% received <400 mug/day). In this group, end-of-study 25(OH)D correlated positively with mean percent increases from baseline in lumbar spine and femoral neck BMD [Pearson correlation coefficients (95% CI) = 0.23 (0.02-0.41) and 0.24 (0.03-0.41), respectively]. Baseline 25(OH)D correlated with increases in only lumbar spine BMD [Pearson correlation coefficient (95% CI) = 0.22 (0.01-0.40)]. No correlations between mean BMD change and 25(OH)D were seen with ALN/D. In conclusion, in postmenopausal women with osteoporosis and low 25(OH)D receiving alendronate and a wide range of vitamin D doses, the increase in lumbar spine and femoral neck BMD was positively correlated with serum 25(OH)D achieved by the end of the study and, to some extent, with 25(OH)D concentrations at baseline. The degree of success of alendronate therapy for osteoporosis may depend on the vitamin D status of patients. [less ▲]

Detailed reference viewed: 37 (2 ULg)